Commonwealth Equity Services LLC Has $3.04 Million Position in Exelixis, Inc. (NASDAQ:EXEL)

Commonwealth Equity Services LLC grew its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 4.1% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 128,033 shares of the biotechnology company’s stock after purchasing an additional 5,037 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Exelixis were worth $3,038,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Mariner LLC boosted its holdings in Exelixis by 11.8% during the third quarter. Mariner LLC now owns 19,953 shares of the biotechnology company’s stock valued at $436,000 after purchasing an additional 2,113 shares in the last quarter. Natixis Advisors L.P. raised its stake in shares of Exelixis by 8.2% in the third quarter. Natixis Advisors L.P. now owns 25,384 shares of the biotechnology company’s stock valued at $555,000 after acquiring an additional 1,931 shares during the last quarter. Treasurer of the State of North Carolina raised its stake in shares of Exelixis by 0.5% in the third quarter. Treasurer of the State of North Carolina now owns 145,343 shares of the biotechnology company’s stock valued at $3,176,000 after acquiring an additional 738 shares during the last quarter. Qube Research & Technologies Ltd raised its position in Exelixis by 481.2% in the 3rd quarter. Qube Research & Technologies Ltd now owns 115,296 shares of the biotechnology company’s stock worth $2,519,000 after purchasing an additional 95,460 shares during the last quarter. Finally, Lazard Asset Management LLC raised its position in Exelixis by 34.4% in the 3rd quarter. Lazard Asset Management LLC now owns 24,865 shares of the biotechnology company’s stock worth $543,000 after purchasing an additional 6,364 shares during the last quarter. 85.27% of the stock is owned by institutional investors and hedge funds.

Exelixis Stock Up 0.1 %

Exelixis stock traded up $0.02 during midday trading on Friday, hitting $21.98. 152,111 shares of the stock were exchanged, compared to its average volume of 2,130,382. Exelixis, Inc. has a 52-week low of $18.64 and a 52-week high of $24.34. The stock has a market capitalization of $6.66 billion, a price-to-earnings ratio of 34.31, a price-to-earnings-growth ratio of 0.54 and a beta of 0.54. The business’s 50-day moving average price is $21.76 and its 200-day moving average price is $22.31.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Tuesday, April 30th. The biotechnology company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.28 by ($0.16). Exelixis had a return on equity of 8.85% and a net margin of 11.10%. The firm had revenue of $425.23 million for the quarter, compared to analysts’ expectations of $461.04 million. During the same quarter last year, the firm posted $0.12 earnings per share. The firm’s revenue for the quarter was up 4.0% compared to the same quarter last year. On average, sell-side analysts predict that Exelixis, Inc. will post 1.15 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Jack L. Wyszomierski sold 8,287 shares of the business’s stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $22.00, for a total transaction of $182,314.00. Following the transaction, the director now directly owns 349,499 shares in the company, valued at $7,688,978. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Exelixis news, Director Jack L. Wyszomierski sold 8,287 shares of Exelixis stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $22.00, for a total value of $182,314.00. Following the sale, the director now owns 349,499 shares of the company’s stock, valued at $7,688,978. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director George Poste sold 11,686 shares of the business’s stock in a transaction that occurred on Tuesday, May 21st. The shares were sold at an average price of $20.96, for a total transaction of $244,938.56. Following the completion of the sale, the director now directly owns 213,907 shares in the company, valued at approximately $4,483,490.72. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 30,896 shares of company stock worth $660,677. 2.85% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts have commented on EXEL shares. JMP Securities reaffirmed a “market outperform” rating and set a $27.00 target price on shares of Exelixis in a report on Wednesday, April 10th. TD Cowen upped their target price on shares of Exelixis from $25.00 to $27.00 and gave the stock a “buy” rating in a research note on Wednesday, May 1st. William Blair reaffirmed an “outperform” rating on shares of Exelixis in a research note on Wednesday, May 1st. StockNews.com raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Thursday, June 27th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $28.00 target price on shares of Exelixis in a report on Friday, May 3rd. Seven investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Exelixis currently has an average rating of “Moderate Buy” and an average price target of $26.13.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.